| scholarly article | Q13442814 |
| P356 | DOI | 10.3109/09273948.2012.684736 |
| P8608 | Fatcat ID | release_wuag4eevnrg75not6x52f462ha |
| P698 | PubMed publication ID | 22621209 |
| P2093 | author name string | Denis Wakefield | |
| Peter McCluskey | |||
| Ahmed Abu El-Asrar | |||
| P2860 | cites work | Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype? | Q28372707 |
| Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data | Q31044246 | ||
| Neonatal outcome in patients with rheumatic disease | Q33363243 | ||
| Adoptive-transfer effects of intravenous immunoglobulin in autoimmunity | Q33389188 | ||
| The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation | Q33867433 | ||
| Intravenous immunoglobulin and idiopathic secondary recurrent miscarriage: a multicentered randomized placebo-controlled trial | Q34071163 | ||
| Teratogen update: azathioprine and 6-mercaptopurine. | Q34124884 | ||
| Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus | Q34127522 | ||
| Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept | Q34595156 | ||
| Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease | Q34632049 | ||
| Nonsteroidal anti-inflammatory drugs and reversible female infertility: is there a link? | Q34734826 | ||
| Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother | Q34740297 | ||
| Glucocorticoid Therapy for Rheumatic Diseases: Maternal, Fetal, and Breast‐Feeding Considerations | Q35177018 | ||
| Treatment With Immunosuppressive and Disease Modifying Drugs During Pregnancy and Lactation | Q35177028 | ||
| Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial. | Q35546634 | ||
| Pregnancy in patients with rheumatic disease: anti-inflammatory cytokines increase in pregnancy and decrease post partum | Q35555622 | ||
| A correlation of pregnancy term, disease activity, serum female hormones, and cytokines in uveitis | Q35592669 | ||
| Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study | Q35638594 | ||
| The use of medications for inflammatory bowel disease during pregnancy and nursing | Q36249913 | ||
| Antirheumatic drugs in pregnancy and lactation | Q36272347 | ||
| Pregnancy and breastfeeding in patients with Crohn's disease | Q37073424 | ||
| Immunosuppressive therapy for ocular diseases | Q37293772 | ||
| Pregnancy and rheumatic disease: "by the book" or "by the doc". | Q37318777 | ||
| Biologic therapy and pregnancy outcomes in women with rheumatic diseases | Q37465030 | ||
| Fertility concerns and preservation in younger women with breast cancer | Q37703834 | ||
| Antirheumatic medication during lactation | Q39824200 | ||
| Clinical teratology counseling and consultation case report: low dose methotrexate exposure in the early weeks of pregnancy | Q40844061 | ||
| Effects of immunosuppressive drugs during pregnancy | Q41145652 | ||
| Maternal corticosteroid use and risk of selected congenital anomalies | Q41689861 | ||
| Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options? | Q41925126 | ||
| Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn | Q44677102 | ||
| Effects of cyclophosphamide on fertility and general reproductive performance of rats | Q45041287 | ||
| Disease specific problems related to drug therapy in pregnancy | Q45107051 | ||
| Noninfectious uveitis and pregnancy | Q47792855 | ||
| Analysis of 100 pregnancy outcomes in women treated systemically with tacrolimus | Q47866297 | ||
| Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study. | Q50545337 | ||
| Interferon-alpha--a new therapeutic option in refractory juvenile Behçet's disease with CNS involvement. | Q53215318 | ||
| A dwell position verification method for high dose rate brachytherapy. | Q53592351 | ||
| Azathioprine and breastfeeding-is it safe? | Q56785730 | ||
| P433 | issue | 4 | |
| P921 | main subject | eye disease | Q3041498 |
| reproductive age | Q109745023 | ||
| P304 | page(s) | 277-287 | |
| P577 | publication date | 2012-05-23 | |
| P1433 | published in | Ocular Immunology and Inflammation | Q15760486 |
| P1476 | title | Treatment of severe inflammatory eye disease in patients of reproductive age and during pregnancy | |
| P478 | volume | 20 |
| Q36293855 | Novel CD28 antagonist mPEG PV1-Fab' mitigates experimental autoimmune uveitis by suppressing CD4+ T lymphocyte activation and IFN-γ production |
| Q42253693 | The course of uveitis in pregnancy and postpartum. |
| Q38464355 | Treatment of severe non-infectious uveitis in high-risk conditions (Part I): pregnancy and malignancies, management and safety issues |
| Q38806044 | Unmet Needs and Future Directions in Inflammatory Eye Disease |
| Q26864267 | Uveitis and gender: the course of uveitis in pregnancy |
Search more.